The Patent Finder

Terms ending in 2038

Epicentrx, Inc.

Every in-force patent on Epicentrx, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,291,726A549 Host Cells Comprising a Recombinant Oncolytic Adenovirus with Modified E1A Cancer-Specific Promoter
In force
 · High confidence
Epicentrx, Inc.In forceHigh confidence
US 11,576,895Compositions and Methods for Intravenous Administration of 2-Bromo-1-(3,3-Dinitroazetidin-1-YL)ETHANONE
In force
 · High confidence
Epicentrx, Inc.In forceHigh confidence
US 11,834,492Human IL-10 Receptor Alpha Fusion Proteins
In force
 · High confidence
Epicentrx, Inc.In forceHigh confidence
US 11,744,859Compositions and Methods for Parenteral Administration of Therapeutic Agents
In force
 · High confidence
Epicentrx, Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited